Find More Contacts for RegeneMed
Protected Content
Owner
Non-Management, Executive Management, Operations
3 emails found 1 phone number found
View contacts for RegeneMed to access new leads and connect with decision-makers.
View All Contacts
  • Company Type For Profit
  • Contact Email info@regenemed.com
  • Phone Number 8582009531

RegeneMed accelerates the development of safer, more effective drugs by providing integrated high throughput platforms incorporating engineered human tissue-based assays. Their patented, proprietary, core technologies enable in vitro growth of engineered human tissues, including liver, GI tract, bone marrow, blood-brain barrier, cardiovascular and

neuronal. The first and critical application of these tissue-based in vitro model systems is to replace cell-based assays and animal testing to debottleneck ADME/Tox evaluation, the leading cause of drug failures facing the pharmaceutical industry.

Lists Featuring This Company

Greater San Diego Area Health Care Companies
2,957 Number of Organizations • $46.1B Total Funding Amount • 2,210 Number of Investors
Greater San Diego Area Companies With Fewer Than 50 Employees (Top 10K)
9,971 Number of Organizations • $21.7B Total Funding Amount • 3,560 Number of Investors
Western US Biotechnology Companies
6,065 Number of Organizations • $269.5B Total Funding Amount • 13,634 Number of Investors
Greater San Diego Area Companies With Fewer Than 1000 Employees (Top 10K)
9,812 Number of Organizations • $93.8B Total Funding Amount • 5,998 Number of Investors

Frequently Asked Questions

Where is RegeneMed's headquarters? RegeneMed is located in San Diego, California, United States.Who invested in RegeneMed? RegeneMed is funded by Tech Coast Angels.How much funding has RegeneMed raised to date? RegeneMed has raised .When was the last funding round for RegeneMed? RegeneMed closed its last funding round on Jan 1, 2007 from a Venture - Series Unknown round.Who are RegeneMed's competitors? Alternatives and possible competitors to RegeneMed may include Gene Sciences, Inc..